Selective oestrogen receptor degrader (SERD)
Drugs that do not just block the oestrogen receptor but mark it for destruction, so the cancer cell loses the receptor altogether. The new oral versions work even when the receptor has mutated (ESR1) to escape older hormone pills.
Fulvestrant (2002) is an injectable SERD limited by incomplete degradation; elacestrant (2023, EMERALD) was the first oral SERD, approved for ESR1-mutant metastatic disease, followed by camizestrant (SERENA-6, switching at ctDNA-detected ESR1 mutation), imlunestrant and vepdegestrant (a PROTAC). Oral SERDs are now in adjuvant trials (CAMBRIA, lidERA) and in combinations with CDK4/6 and PI3K/AKT inhibitors. Tamoxifen is the older selective modulator (SERM) that blocks the receptor in breast but stimulates it in bone and uterus.
Pages like this
not linked directly; found by shared links- PersonFrançois-Clément Bidard
Shares EMERALD, Fulvestrant, Elacestrant, Estrogen receptor (ERα).
- TermESR1 mutation
Shares EMERALD, Elacestrant, SERENA-6, Estrogen receptor (ERα).
- TermOral SERD
Shares Fulvestrant, Elacestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- Key paperIBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years
Shares Tamoxifen, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialVERITAC-2
Shares Fulvestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- InstitutionBarbara Ann Karmanos Cancer Institute
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- ProductGoserelin / leuprolide (ovarian function suppression)
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaLow-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.